Management and treatment of chronic urticaria (CU)
- 4 June 2015
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 29 (S3) , 16-32
Abstract
Developments increasing our understanding of chronic urticaria have resulted in the simplification and improvement of available treatments. Currently, many treatments target mast cell mediators, but we can now disrupt mast cell activation with the anti‐IgE antibody omalizumab, which has markedly advanced the treatment landscape for patients with difficult‐to‐treat urticaria. Current guidelines provide a framework for the management and treatment of patients with CU but, as each patient is different, knowledge and experience of specialist dermatologists and allergists are key to effective pharmacotherapy. This article reviews the different therapeutic options for patients with chronic spontaneous urticaria (also called chronic idiopathic urticaria) or chronic inducible urticaria and discusses management of special populations or special circumstances related to CU.Keywords
Funding Information
- Novartis Pharma AG
This publication has 139 references indexed in Scilit:
- Up‐dosing with bilastine results in improved effectiveness in cold contact urticariaAllergy, 2013
- Cholinergic urticaria responding to botulinum toxin injection for axillary hyperhidrosisBritish Journal of Dermatology, 2013
- Mast cells and inflammationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Failure of omalizumab (Xolair®) in the treatment of a case of solar urticaria caused by ultraviolet A and visible lightPhotodermatology, Photoimmunology & Photomedicine, 2011
- A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticariaJournal of Allergy and Clinical Immunology, 2011
- IgE, mast cells, basophils, and eosinophilsJournal of Allergy and Clinical Immunology, 2010
- Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticariaAnnals of Allergy, Asthma & Immunology, 2010
- The safety of cetirizine during pregnancyReproductive Toxicology, 2008
- Cyclosporin A therapy for severe solar urticariaPhotodermatology, Photoimmunology & Photomedicine, 1997
- Excretion of Loratadine in Human Breast MilkThe Journal of Clinical Pharmacology, 1988